¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antipernicious anaemia factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • occupancy factor
    °ÅÁÖ°è¼ö
  • obliquity factor
    ±â¿ï±â°è¼ö
  • output factor
    Ãâ·ÂÀÎÀÚ
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet factor 3
    Ç÷¼ÒÆÇÀÎÀÚ3
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ4
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ħÀüÀÎÀÚ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • prolactin releasing factor
    ÇÁ·Î¶ôƾºÐºñÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • prolactin releasing factor
    ÇÁ·Î¶ôƾºÐºñÀ¯¹ßÀÎÀÚ
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
  • psychogenic factor
    Á¤½Å¼º¿ä¼Ò
  • psychological factor
    ½É¸®¿ä¼Ò
  • psychosocial factor
    ½É¸®»çȸÀû¿äÀÎ
  • quality factor
    Áú¿ä¼Ò, Á¤¼ºÀÎÀÚ
  • racial factor
    ÀÎÁ¾¿äÀÎ
  • radiation weighting factor
    ¹æ»ç¼±°¡Áß°è¼ö
  • realization factor
    ½ÇÇöÀÎÀÚ
  • recruitment factor
    µ¿¿øÀÎÀÚ
  • reducing factor
    ȯ¿øÀÎÀÚ
  • reinforcing factor
    °­È­¿äÀÎ
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • resistancetransfer factor
    ³»¼ºÀü´ÞÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • growth hormone-releasing factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ<--¹æÃâÀÎÀÚ>
  • growth promoting factor
    ¼ºÀåÃËÁøÀÎÀÚ(à÷íþõµòäì×í­), ¹ßÀ°ÃËÁø¹°Áú(Û¡ëÀõµòäÚªòõ)
  • hageman factor
    ÇϰԸ¸ ÀÎÀÚ, Hageman ÀÎÀÚ
  • hematopoietic growth factor
    Á¶Ç÷¼ºÀåÀÎÀÚ
  • hemorrhagic diathesis,clotting factor abnormalities
    ÀÀ°íÀÎÀÚ ÀÌ»ó
  • hepatocyte growth factor
    °£¼¼Æ÷¼ºÀåÀÎÀÚ
  • histamine sensitizing factor =HSF
    È÷½ºÅ¸¹Î°¨ÀÛÀÎÀÚ(¡­ÊïíÂì×í­).
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • hyperglycemic glycogenolytic factor
    °íÇ÷´ç¼º ´ç¿øºÐÇØ(¼º) ÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ(ë¤×ãì×í­).
  • hypothalamic releasing factor
    ½Ã»óÇϺιæÃâÀÎÀÚ.
  • hypothalamus releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ.
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
  • elongation factor
    ½ÅÀåÀÎÀÚ
  • enabling factor
    ÀÇ·áÀÌ¿ë °¡´É¿äÀÎ.
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ.
  • endothelial cell growth factor
    ³»ÇǼ¼Æ÷ Áõ½ÄÀÎÀÚ
  • endothelium-derived contracting factor (EDCF)
    ³»ÇǼ¼Æ÷¼º¼öÃàÀÎÀÚ(Ò®ù«á¬øààõâ¥õêì×í­)
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ.
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ(¡­ì¬èÐì×í­).
  • endothelium-derived relaxing factor
    ³»ÇÇ ¼¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hyperglycemic factor
    °úÇ÷´ç ÀÎÀÚ(ΦúìÓØì×í­)
  • hypocalcemic factor
    Àú(î¸)Ä®½·Ç÷Áõ(úìñø) ÀÎÀÚ(ì×í­)
  • hypoglycemic factor
    ÀúÇ÷´ç ÀÎÀÚ(î¸úìÓØì×í­)
  • initiation factor
    °³½ÃÀÎÀÚ(ËÒã·ì×í­)
  • instability factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • intrinsic factor
    ³»ÀÎÀÎÀÚ(Ò®ì×ì×í­)
  • labile factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • Laki-Lorand factor
    ¶óŰ-·Î¶õµå ÀÎÀÚ(ì×í­)
  • Lande G factor
    ¶õµ¥ G ÀÎÀÚ(ì×í­)
  • lard factor
    µ·Áö(ÔÊò·) ÀÎÀÚ(ì×í­)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • Lewis factor
    ·çÀ̽ºÀÎÀÚ(ì×í­)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • liver filtrate factor
    °£ ¿©°ú ÀÎÀÚ(ÊÜÕëΦì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
PIF   1) Proliferation Inhibitory Factor
  2) Prolactin release Inhibiting Factor...
P-P factor Pellagra Preventive factor
  = Vitamin G
PTC   1) Percutaneous Transhepatic Cholangiography
    = PTHC
 ...
TDF Testicular-Determining Factor
  = HY Factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
VEGF/VPF Vascular endothelial growth factor/ vascular permeability factor
VPF/VEGF Vascular permeability factor/vascular endothelial growth factor
Factor XII factor
EGF 125)I-epidermal growth factor
NGF 125)I-nerve growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • limiting factor
    ÇѰè ÀÎÀÚ, Á¦ÇÑ ÀÎÀÚ, ÇÑÁ¤ ÀÎÀÚ
  • local etiologic factor
    ±¹¼ÒÀû ¿øÀÎ ¿ä¼Ò
  • local factor
    ±¹¼Ò ¿äÀÎ
  • lytic factor
    ¿ëÇØ ÀÎÀÚ
  • macrophage activating factor
    ´ë½Ä ¼¼Æ÷ Ȱ¼º ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ, °Å½Ä ¼¼Æ÷ À¯ÁÖ ¾ïÁ¦ ÀÎÀÚ
  • maturation factor
    ¼º¼÷ ÀÎÀÚ
  • mediating factor
    ¸Å°³ ¿äÀÎ
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • milk factor
    ¸ðÀ¯ ÀÎÀÚ
  • monocytosis-producing factor
    ´ÜÇÙ±¸ Áõ°¡Áõ À¯¹ß ÀÎÀÚ
  • multiple factor
    ´Ù¹ß¼º ÀÎÀÚ
  • myocardial depressant factor
    ½É±Ù ¾ïÁ¦ ÀÎÀÚ
  • natural moistening factor
    ÀÚ¿¬ º¸½À ÀÎÀÚ
  • negative cognitive factor
    ºÎÁ¤ÀûÀÎ ÀÎ½Ä ¿äÀεé
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
sideroblastic anaemia <haematology> A form of refractory anaemia caused by sideroblasts in the bone marrow.
Origin: Gr. Haima = blood
(09 Oct 1997)
hyperchromic anaemia <haematology> A type of anaemia which results when the body lacks sufficient vitamin B and the resulting red blood cells are thicker than normal, appearing more deeply coloured.
Origin: Gr. Haima = blood
(11 Jan 1998)
hypochromic anaemia Anaemia characterised by a decrease in the ratio of the weight of haemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular haemoglobin concentration is less than normal; the individual cells contain less haemoglobin than they could have under optimal conditions.
(05 Mar 2000)
hypochromic microcytic anaemia Anaemia due to iron deficiency or thalassaemia, and characterised by lower than normal mean corpuscular volume, mean corpuscular haemoglobin, and mean corpuscular haemoglobin concentration.
(05 Mar 2000)
hypoferric anaemia Hypochromic microcytic anaemia characterised by low serum iron, increased serum iron-binding capacity, decreased serum ferritin, and decreased marrow iron stores.
Synonym: hypoferric anaemia.
(05 Mar 2000)
hypoplastic anaemia <haematology> A low red blood cell count that results from the underproduction of red blood cells by the bone marrow. This is often secondary to a drug (chemotherapy) side effect.
(27 Sep 1997)
hypoproliferative anaemia <haematology> Anaemia which results from abnormally low levels of red blood cells and haemoglobin in the blood. It is caused because the person has too few of the stem cells which make the red blood cells.
(09 Oct 1997)
slaty anaemia An ash-gray pallor in poisoning from acetanelid or silver (argyria).
(05 Mar 2000)
spastic anaemia Local anaemia resulting from nontransitory contraction of the arterial vessels in the affected region.
(05 Mar 2000)
spherocytic anaemia <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
splenic anaemia <syndrome> Chronic congestive splenomegaly that occurs primarily in children as a sequel to hypertension in the portal or splenic veins, usually as a result of thrombosis of the veins; anaemia, splenomegaly, and irregular episodes of gastrointestinal bleeding are usually observed, with ascites, jaundice, leukopenia, and thrombocytopenia developing in various conbinations.
Synonym: Banti's disease, splenic anaemia.
(05 Mar 2000)
neonatal anaemia <haematology> A condition which develops in the foetus due to an incompatibility between the mother's blood type (RH factor) and the baby's. Maternal antibodies, which enter the foetal circulation during delivery attack the baby's red blood cells leading to haemolysis (rupture of the cells).
Symptoms include an infant with an enlarged liver and spleen, swelling, jaundice and anaemia.
(27 Sep 1997)
normochromic anaemia Any anaemia in which the concentration of haemoglobin in the erythrocytes is within the normal range, i.e., the mean corpuscular haemoglobin concentration is from 32 to 36%.
Synonym: isochromic anaemia.
(05 Mar 2000)
normocytic anaemia Any anaemia in which the erythrocytes are normal in size, i.e., the mean corpuscular volume ranges from 82 to 92 cu um.
(05 Mar 2000)
nutritional anaemia Any anaemia resulting from a dietary deficiency of materials essential to red blood cell formation, e.g., iron, vitamins (especially folic acid), protein.
Synonym: deficiency anaemia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á